Highly experienced Project Director and Clinical Team Leader with over 30 years’ broad experience in the pharmaceutical industry; spanning both large pharma and small-medium enterprises (SMEs), leading development projects from discovery to lifecycle management in a variety of therapeutic areas.
After an early lab based career with SmithKline & French, worked for 20 years with GlaxoSmithKline seeing that organisation grow from modest beginnings as Glaxo Group Research into GlaxoWellcome, and then GSK, gaining broad experience in respiratory, GI and CNS therapy areas. Highlights including delivery of the migraine products, Imigran®, and Naraming® to the market in the 1990s, and helping embed the Psychiatry Centre of Excellence for Drug Discovery in the early years of GSK.
After a couple of years experiencing the varied life of an SME working as Clinical Development Director with an Anglo-Japanese pharmacogenomics life sciences company PGXIS, joined Norgine as Therapy Area Director in April 2011. Helped Norgine transition through a period of organisational change embedding a shift from line to matrix working. Currently heading the Clinical Development group, with personal responsibilities for line management, GCP, service provider selection and Sponsor oversight. The role also includes matrix management governance responsibilities for a variety of projects in gastroenterology, hepatology and critical care, with experience including medicinal products, medical devices, diagnostics and advanced therapeutic medicinal products (ATMPs). Recent highlight seeing PLENVU® gain both EU MAA & US NDA approvals & subsequent launches of the world’s first 1L bowel preparation in 2018.
Outside of work, my wife and 4 children are my most precious concerns, and as the children grow towards independence, tennis is a passion and golf an enigma, both yet to be conquered to any degree of satisfaction!